Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Cingulate Inc.

Cingulate® is a biopharmaceutical company utilizing its innovative Precision Timed Release™ (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products.  
 
We aim to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.  
 
With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), we believe there are multiple therapeutic areas where our PTR technology may be employed to develop additional product candidates, notably anxiety disorders.

Today we announced the successful manufacturing of CTx-1301 doses for both of our upcoming pivotal Phase 3 trials in pediatric and adolescents with #ADHD, with the fixed-dose study scheduled to begin the week of July 24.
 
Learn more: https://lnkd.in/exPF-XFW
$CING

Our Chairman and CEO, Shane Schaffer, will participate in a company discussion at the Maxim Group's Virtual Healthcare Conference tomorrow. 

To attend, register as an M-Vest member and reserve your seat here: https://lnkd.in/egF5_946
$CING #ADHD

Today we announced the completion of our Phase 3 trial evaluating the onset and duration of CTx-1301 in adults with #ADHD. Results are expected 3Q 2023.
 
Learn more: https://lnkd.in/ev_kre_W
$CING

Catch the live replay from Benzinga All Access this week to hear Shane Schaffer, $CING CEO, and Tim Moore, SVP of Biotech at Indegene, discuss our joint commercialization agreement and how we’ll leverage #AI to launch in the $20B #ADHD market: https://lnkd.in/e9pkPHhW

Our CEO, Shane Schaffer, joined fellow Kansas Citian and Royals broadcaster, Joel Goldberg, for an episode of his “Rounding The Bases” podcast. 

Listen to learn about our work in #ADHD and ambitions to become a powerhouse in the pharmaceutical industry – right from #KansasCity.

Today we announced first quarter 2023 financial results, including clinical and business updates on the Phase 3 program for our lead candidate, CTx-1301, for the treatment of #ADHD.

Read our press release to learn more: https://lnkd.in/eyzmJnkn
$CING

Our CEO, Shane Schaffer, stopped by Nasdaq’s Innovators with Jane King to discuss how we’re tackling unmet needs in #ADHD with our lead candidate CTx-1301 (dexmethylphenidate).

Watch the full video: https://lnkd.in/ej8aanrP
$CING

Today we announced the successful transfer of CTx-1301 proprietary Precision Timed Release™ manufacturing processes to Societal CDMO, keeping us on track to meet previously announced clinical timelines for our Phase 3 program in #ADHD. 

Learn more: https://lnkd.in/d36fuHaW
$CING Societal™ CDMO

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue	178.91K -	842.35K 370.82%	808.44K 4.03%	621.99K 23.06%	582.92K 6.28%
gross profit	-178.91K -	-842.35K 370.82%	-808.44K 4.03%	-621.99K 23.06%	-582.92K 6.28%
selling and marketing expenses	250K -				-583.03K -
general and administrative expenses	2.30M -	1.99M 13.51%	12.27M 516.22%	8.51M 30.67%	7.27M 14.58%
selling general and administrative expenses	2.55M -	1.99M 21.98%	12.27M 516.22%	8.51M 30.67%	6.68M 21.44%
research and development expenses	9.09M -	5.09M 44.00%	8.41M 65.13%	9.00M 6.95%	15.49M 72.24%
other expenses
cost and expenses	11.65M -	7.08M 39.17%	20.68M 191.91%	17.50M 15.37%	22.76M 30.04%
operating expenses	11.65M -	7.08M 39.17%	20.68M 191.91%	17.50M 15.37%	22.18M 26.71%
interest expense		54.60K -	-31K 156.77%	174K 661.29%	-776K 545.98%
ebitda	-11.47M -	-6.42M 44.03%	-19.97M 211.16%	-17.50M 12.37%	-22.18M 26.71%
operating income	-11.65M -	-7.08M 39.18%	-20.68M 191.94%	-17.50M 15.37%	-22.76M 30.04%
depreciation and amortization	179.35K -	665.12K 270.86%	708.23K 6.48%	394.01K 44.37%	582.92K 47.94%
total other income expenses net	101.40K -	-101.17K 199.77%	-30.59K 69.76%	-174.51K 470.44%	-775.76K 344.52%
income before tax	-11.55M -	-7.18M 37.77%	-20.71M 188.26%	-17.68M 14.65%	-23.53M 33.14%
income tax expense	-100.53K -	99.34K 198.82%	30.50K 69.29%	174K 470.45%	2 100.00%
net income	-11.45M -	-7.28M 36.36%	-20.74M 184.75%	-17.85M 13.94%	-23.53M 31.85%
weighted average shs out	1.06M -	565.47K 46.48%	565.47K 0%	565.47K 0%	905.23K 60.08%
weighted average shs out dil	1.06M -	565.47K 46.48%	565.47K 0%	565.47K 0%	905.23K 60.08%
eps	-10.83 -	-12.88 18.93%	-36.68 184.78%	-31.57 13.93%	-26 17.64%
epsdiluted	-10.83 -	-12.88 18.93%	-36.68 184.78%	-31.57 13.93%	-26 17.64%

COM:CINGULATE

Cingulate Inc.

Last Close

0.37

26/07 20:00

Market Cap

4.76M

Beta: -

Volume Today

292.55K

Avg: -

Preview